

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

NCT07265479

Status	RECRUITING
Phase	Phase 3
Sponsor	Organon and Co
Enrollment	180 participants

Key Eligibility Criteria

Inclusion (4)

- Infants and toddlers born at term (e37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
- Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
- Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
- Legal guardian or primary caregiver is able and willing to adhere to protocol requirements

Exclusion (10)

- Significant neurological disorder or history of seizure
 - Know clinically significant cardiac rhythm or cardiac disorder
 - History of sudden infant death in a sibling
 - Clinically significant chromosome abnormality
 - History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
- ... and 5 more (see full listing online)

Locations (48 total)

AllerVie Clinical Research, Birmingham, Alabama, United States
Dermatology Trial Associates, Bryant, Arkansas, United States
Dermatology Research Associates, Los Angeles, California, United States
... and 45 more locations